HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 7912166.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Previously, we have reported a correlation between the expression of HER2/neu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2/neu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infiltrating lymphocytes of HLA-A2+ HER2/neu+ NSCLC patients. These CTL lines specifically recognized HLA-A2+ HER2/neu+ autologous and allogeneic NSCLC cell lines as well as HLA-A2+ HER2/neu+ heterologous ovarian cancer cell lines. Furthermore, these CTL recognized an overexpressed, HER2/neu-derived peptide. From these results, we conclude that HLA-A2 serves as a restriction element in NSCLC. More importantly, at least one HER2/neu-derived peptide is a tumor-associated antigen in NSCLC and ovarian cancer.
Medical subject headings
- Antigens, Neoplasm
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- HLA-A2 Antigen
- Lung Neoplasms
- Ovarian Neoplasms
- Proto-Oncogene Proteins
- T-Lymphocytes, Cytotoxic